Published in Mov Disord on December 15, 2010
Dystonia and Tremor: The Clinical Syndromes with Isolated Tremor. Tremor Other Hyperkinet Mov (N Y) (2016) 0.76
Sensory trick with metoclopramide-associated tardive tremor. BMJ Case Rep (2012) 0.75
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Transportin-SR2 imports HIV into the nucleus. Curr Biol (2008) 2.35
PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol (2004) 2.30
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol (2008) 1.96
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians. Eur J Hum Genet (2005) 1.71
PARK6-linked parkinsonism occurs in several European families. Ann Neurol (2002) 1.68
Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain (2010) 1.66
Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures. Surgery (2002) 1.65
Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol (2011) 1.62
Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. Ann Neurol (2004) 1.51
Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol (2002) 1.51
A case of dementia parkinsonism resembling progressive supranuclear palsy due to mutation in the tau protein gene. Arch Neurol (2003) 1.49
Pathological gambling in Parkinson's disease: subthalamic oscillations during economics decisions. Mov Disord (2013) 1.45
Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol (2012) 1.39
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord (2002) 1.28
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon (2013) 1.27
Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology (2003) 1.23
Health-related quality of life in multiple system atrophy. Mov Disord (2006) 1.11
Mutation screening of the DYT6/THAP1 gene in Italy. Mov Disord (2009) 1.11
Dendrimer internalization and intracellular trafficking in living cells. Mol Pharm (2010) 1.11
The diagnostic challenge of primary dystonia: evidence from misdiagnosis. Mov Disord (2010) 1.10
A neurophysiological study of myoclonus in patients with DYT11 myoclonus-dystonia syndrome. Mov Disord (2008) 1.06
Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci (2012) 1.06
PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. Hum Mutat (2008) 1.06
Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Mov Disord (2009) 1.06
Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. Mov Disord (2009) 1.05
Is this dystonia? Mov Disord (2009) 1.03
Synergistic control of protein kinase Cgamma activity by ionotropic and metabotropic glutamate receptor inputs in hippocampal neurons. J Neurosci (2006) 1.01
Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol (2012) 0.99
Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon (2012) 0.98
Inclusion and exclusion criteria for DBS in dystonia. Mov Disord (2011) 0.97
Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol (2011) 0.97
Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci (2013) 0.97
Non-DYT1 early-onset primary torsion dystonia: comparison with DYT1 phenotype and review of the literature. Mov Disord (2006) 0.97
Analysis of blink rate in patients with blepharospasm. Mov Disord (2006) 0.97
Conflict-dependent dynamic of subthalamic nucleus oscillations during moral decisions. Soc Neurosci (2010) 0.94
GCN5-dependent acetylation of HIV-1 integrase enhances viral integration. Retrovirology (2010) 0.93
Targeting the brain: considerations in 332 consecutive patients treated by deep brain stimulation (DBS) for severe neurological diseases. Neurol Sci (2012) 0.90
Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol (2013) 0.90
Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. Mov Disord (2009) 0.90
Analysis of ferritin genes in Parkinson disease. Clin Chem Lab Med (2007) 0.89
Levodopa-induced dyskinesias and their management. J Neurol (2008) 0.89
In vivo evidence for GABA(A) receptor changes in the sensorimotor system in primary dystonia. Mov Disord (2011) 0.87
Primary focal hyperhidrosis in a new family not linked to known loci. Dermatology (2012) 0.85
Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports. J Neurol (2010) 0.85
Presumptive myocarditis with ST-Elevation myocardial infarction presentation in young males as a new syndrome. Clinical significance and long term follow up. Cardiovasc Ultrasound (2011) 0.85
Phenotypic characterization of DYT13 primary torsion dystonia. Mov Disord (2004) 0.84
"Gluing" phenotypes together: the case of GLUT1. Neurology (2011) 0.84
Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord (2009) 0.83
Disability and profiles of functioning of patients with Parkinson's disease described with ICF classification. Int J Rehabil Res (2011) 0.83
Subclinical sensory abnormalities in unaffected PINK1 heterozygotes. J Neurol (2008) 0.83
Transient gender-related effects in Parkinson's disease patients with subthalamic stimulation. J Neurol (2009) 0.83
Deep brain stimulation for movement disorders. Considerations on 276 consecutive patients. J Neural Transm (Vienna) (2011) 0.82
Epidural premotor cortical stimulation in primary focal dystonia: clinical and 18F-fluoro deoxyglucose positron emission tomography open study. Mov Disord (2012) 0.82
Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. Mov Disord (2005) 0.82
Update on dystonia. Curr Opin Neurol (2012) 0.82
Quantitative analysis of Tat peptide binding to import carriers reveals unconventional nuclear transport properties. J Biol Chem (2011) 0.82
Designing clinical trials for dystonia. Neurotherapeutics (2014) 0.82
Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson's disease. Mov Disord (2006) 0.81
Alpha-synuclein gene duplication: marked intrafamilial variability in two novel pedigrees. Mov Disord (2013) 0.80
Advances in the genetics of primary torsion dystonia. F1000 Biol Rep (2010) 0.80
Impact of nonmotor symptoms on disability in patients with Parkinson's disease. Int J Rehabil Res (2011) 0.80
Abnormal gating of somatosensory inputs in essential tremor. Clin Neurophysiol (2003) 0.80
Clinical management of pain and fatigue in Parkinson's disease. Parkinsonism Relat Disord (2012) 0.80
Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord (2011) 0.79
Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon (2009) 0.79
Cortical myoclonus in childhood and juvenile onset Huntington's disease. Parkinsonism Relat Disord (2012) 0.79
STN DBS in PD: selection criteria for surgery should include cognitive and psychiatric factors. Neurology (2006) 0.79
Genome-wide association study in musician's dystonia: a risk variant at the arylsulfatase G locus? Mov Disord (2013) 0.79
Mood disorder following DBS of the left amygdaloid region in a dystonia patient with a dislodged electrode. Mov Disord (2008) 0.78
Phenotypic variability of DYT1-PTD: does the clinical spectrum include psychogenic dystonia? Mov Disord (2002) 0.78
Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. Mov Disord (2004) 0.77
Unique properties of botulinum toxins. Toxicon (2009) 0.77
Functioning and disability in Parkinson's disease. Disabil Rehabil (2010) 0.77
Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am J Gastroenterol (2003) 0.76
Early visual memory deficits: a neuropsychological marker of GBA mutations in PD? Neurology (2012) 0.76
High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. J Neurol (2005) 0.76
Attentional networks in Parkinson's disease. Behav Neurol (2013) 0.76
Pre-operative evaluations for DBS in dystonia. Mov Disord (2011) 0.75
Can falls be prevented in Parkinson's disease? J Neurol Neurosurg Psychiatry (2007) 0.75
Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: need for long-term clinical trials. Mov Disord (2011) 0.75
Choice-option evaluation is preserved in early Huntington and Parkinson's disease. Neuroreport (2011) 0.75
Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease. Neuropsychologia (2012) 0.75
Guest editors' introduction. Mov Disord (2011) 0.75
Normal cardiovascular reflex testing in patients with parkin disease. Mov Disord (2007) 0.75
Reliability and validity of the range of motion scale (ROMS) in patients with abnormal postures. Pain Med (2014) 0.75
Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease. Neurol Sci (2011) 0.75
Rivastigmine in Parkinson's disease dementia. Expert Rev Neurother (2008) 0.75
Diagnostic issues in childhood and adult dystonia. Expert Opin Med Diagn (2011) 0.75
Cutaneous herpes zoster and implantable pulse generator. Neuromodulation (2009) 0.75
Ambiguous idiom processing in Parkinson's disease patients. Cogn Neuropsychol (2014) 0.75
Clinical presentation and progression of sporadic and familial primary torsion dystonia in Italy. Adv Neurol (2004) 0.75
Low-voltage bilateral pallidal stimulation for severe meige syndrome in a patient with primary segmental dystonia: case report. Neurosurgery (2010) 0.75